Want to see COGT full AI Analyst Report?
COGT Stock Chart & Stats
$37.25
-$0.07(-0.91%)
At close: 4:00 PM EST
$37.25
-$0.07(-0.91%)
Day’s Range― - ―
52-Week Range$10.38 - $43.73
Previous CloseN/A
Volume181.15K
Average Volume (3M)2.90M
Market Cap
$6.68B
Enterprise Value$5.68K
Total Cash (Recent Filing)$866.38M
Total Debt (Recent Filing)$238.65M
Price to Earnings (P/E)―
Beta0.96
Next Earnings
Aug 11, 2026EPS Estimate
-0.56Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-3.08
Shares Outstanding170,868,010
10 Day Avg. Volume2,540,359
30 Day Avg. Volume2,902,047
Financial Highlights & Ratios
PEG Ratio-3.81
Price to Book (P/B)3.77
Price to Sales (P/S)0.00
P/FCF Ratio-9.03
Enterprise Value/Market Cap<0.01
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit>-0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$52.43Price Target Upside40.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
EPS Forecast (FY)-2.25
Revenue Forecast (FY)$11.88M
Bulls Say, Bears Say
Bulls Say
Balance Sheet CushionA sizable equity base (~$608M against ~$903M assets) provides a meaningful capital buffer to support ongoing clinical development and operations. This cushion reduces near-term insolvency risk and gives management flexibility to execute trials or seek partnerships without immediate forced dilution.
Governance & Board SupportStrong shareholder backing for directors, auditor ratification, and executive compensation signals governance stability and oversight continuity. That credibility helps with regulatory engagement, partner negotiations, and investor confidence, lowering execution and compliance risk over the medium term.
Focused Precision-Medicine PipelineCogent's targeted small-molecule strategy concentrated on genetically defined, KIT-driven indications creates a clear scientific niche. A focused pipeline can enable efficient resource allocation, clearer regulatory pathways, and potential differentiation if clinical data validate the mechanism, supporting sustainable competitive positioning.
Bears Say
No Revenue & Widening LossesThe company remains entirely pre-commercial with zero product revenue and rapidly widening net losses. Persistent operating deficits mean continued reliance on external capital; absent clinical progress or partnering, this raises dilution risk and constrains long-term strategic options for advancing programs.
Escalating Cash BurnSharp increases in operating outflows and deeply negative free cash flow erode liquidity and shorten runway. Growing cash burn forces management to prioritize programs or seek near-term financings/partnerships, which can delay or scale back development plans and materially affect long-run value creation.
Rising Leverage & Negative ROELeverage has risen materially from prior periods while returns on equity are substantially negative, indicating capital deployed is not generating shareholder value. Higher debt elevates refinancing and covenant risks, increasing the likelihood of dilution or constrained strategic choices if clinical milestones are delayed.
Cogent Biosciences News
COGT FAQ
What was Cogent Biosciences, Inc.’s price range in the past 12 months?
Cogent Biosciences, Inc. lowest stock price was $10.38 and its highest was $43.73 in the past 12 months.
What is Cogent Biosciences, Inc.’s market cap?
Cogent Biosciences, Inc.’s market cap is $6.68B.
When is Cogent Biosciences, Inc.’s upcoming earnings report date?
Cogent Biosciences, Inc.’s upcoming earnings report date is Aug 11, 2026 which is in 21 days.
How were Cogent Biosciences, Inc.’s earnings last quarter?
Cogent Biosciences, Inc. released its earnings results on May 05, 2026. The company reported -$0.53 earnings per share for the quarter, beating the consensus estimate of -$0.533 by $0.003.
Is Cogent Biosciences, Inc. overvalued?
According to Wall Street analysts Cogent Biosciences, Inc.’s price is currently Undervalued.
Does Cogent Biosciences, Inc. pay dividends?
Cogent Biosciences, Inc. does not currently pay dividends.
What is Cogent Biosciences, Inc.’s EPS estimate?
Cogent Biosciences, Inc.’s EPS estimate is -0.56.
How many shares outstanding does Cogent Biosciences, Inc. have?
Cogent Biosciences, Inc. has 170,868,010 shares outstanding.
What happened to Cogent Biosciences, Inc.’s price movement after its last earnings report?
Cogent Biosciences, Inc. reported an EPS of -$0.53 in its last earnings report, beating expectations of -$0.533. Following the earnings report the stock price went up 0.681%.
Which hedge fund is a major shareholder of Cogent Biosciences, Inc.?
Currently, no hedge funds are holding shares in COGT
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Cogent Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$52.43 (40.75% Upside)
$52.43 (40.75% Upside)
Blogger Sentiment
Bullish
COGT Sentiment 70%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Decreased
By 4.9M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▲ 0.2%
Last 30 Days ▲ 0.2%
Technicals
SMA
Positive
20 days / 200 days
Momentum
220.32%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
218.19%
Trailing 12-Months
Company Description
Cogent Biosciences, Inc.
Cogent Biosciences, Inc. is a biotechnology firm dedicated to creating targeted treatments for illnesses rooted in specific genetic anomalies. The company's primary therapeutic candidate is CGT9486, a selective tyrosine kinase inhibitor engineered to block the KIT D816V mutation, a key driver of systemic mastocytosis, along with other KIT exon 17 mutations observed in individuals suffering from advanced gastrointestinal stromal tumors (GIST). Furthermore, Cogent holds a licensing pact with Plexxikon Inc., granting it rights for the investigation, advancement, and marketing of bezuclastinib. Previously known as Unum Therapeutics Inc., the company adopted its current name, Cogent Biosciences, Inc., in October 2020. Established in 2014, Cogent Biosciences is headquartered in Cambridge, Massachusetts.
COGT Stock 12 Month Forecast
Average Price Target
$52.43
▲(40.75% Upside)
Technical Analysis
IDEAYA Biosciences
―
Beam Therapeutics
―
Disc Medicine
―
Harmony Biosciences Holdings
―
Immunocore Holdings
―
Ownership Overview
4.03% Insiders
30.75% Mutual Funds
1.24% Other Institutional Investors
46.86% Public Companies and
Individual Investors